Cargando…

Suppression of Peroxiredoxin 4 in Glioblastoma Cells Increases Apoptosis and Reduces Tumor Growth

Glioblastoma multiforme (GBM), the most common and aggressive primary brain malignancy, is incurable despite the best combination of current cancer therapies. For the development of more effective therapies, discovery of novel candidate tumor drivers is urgently needed. Here, we report that peroxire...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Hyong, Song, Jieun, Alcantara Llaguno, Sheila R., Murnan, Eric, Liyanarachchi, Sandya, Palanichamy, Kamalakannan, Yi, Ji-Yeun, Viapiano, Mariano Sebastian, Nakano, Ichiro, Yoon, Sung Ok, Wu, Hong, Parada, Luis F., Kwon, Chang-Hyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419743/
https://www.ncbi.nlm.nih.gov/pubmed/22916164
http://dx.doi.org/10.1371/journal.pone.0042818
Descripción
Sumario:Glioblastoma multiforme (GBM), the most common and aggressive primary brain malignancy, is incurable despite the best combination of current cancer therapies. For the development of more effective therapies, discovery of novel candidate tumor drivers is urgently needed. Here, we report that peroxiredoxin 4 (PRDX4) is a putative tumor driver. PRDX4 levels were highly increased in a majority of human GBMs as well as in a mouse model of GBM. Reducing PRDX4 expression significantly decreased GBM cell growth and radiation resistance in vitro with increased levels of ROS, DNA damage, and apoptosis. In a syngenic orthotopic transplantation model, Prdx4 knockdown limited GBM infiltration and significantly prolonged mouse survival. These data suggest that PRDX4 can be a novel target for GBM therapies in the future.